Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04822298 · ClinicalTrials.gov registry record · Phase 1
Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04822298 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 3 participants.
The verdict
NCT04822298, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).
Interventions
- DRUG AMG 160
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-08-31 |
| Est. Completion | 2022-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04822298
The ClinicalTrials.gov registry entry for NCT04822298 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 160 is the first listed.
NCT04822298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04822298 about?
NCT04822298 is a clinical study titled "Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer". This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).
What is the current status of trial NCT04822298?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-08-31. Estimated completion is 2022-01-26.
What interventions are being tested in trial NCT04822298?
The interventions under investigation include: AMG 160 (DRUG).
Who is sponsoring clinical trial NCT04822298?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.